局部过敏性鼻炎诊断,管理和研究中的挑战:当前的概念和未来的前景
Mohamad Mahdi Mortada1, Marcin Kurowski1
1Department of Immunology and Allergy, Medical University of Łódź, 92-213 Łódź, Poland.
Medicina (Kaunas, Lithuania)
|May 27, 2023
概括
通过测量鼻特异性IgE (sIgE) 分泌物,可以改善局部过敏性鼻炎 (LAR) 的诊断. 过敏原免疫疗法 (AIT) 显示出对管理LAR症状和改善生活质量的承诺.
科学领域:
- 过敏和免疫学 过敏和免疫学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
背景情况:
- 局部过敏性鼻炎 (LAR) 的特点是没有全身敏感性的过敏症状.
- 目前的诊断依赖于症状和负面的过敏测试,可能缺少局部反应.
- 鼻特异性免疫球蛋白E (sIgE) 的评估正在成为一种诊断工具.
研究的目的:
- 审查LAR的历史背景,流行病学和病理生理学.
- 评估局部粘膜IgE评估在LAR诊断中的作用.
- 讨论当前和未来的治疗方案,包括过敏原免疫疗法 (AIT).
主要方法:
- 对LAR诊断和管理研究的文献综述.
- 对鼻子SIGE分泌物研究的分析,以应对虫,花粉和菌等过敏原.
- 审查LAR对生活质量的影响.
主要成果:
- 鼻腔sIgE评估显示了作为LAR的额外诊断标准的潜力.
- 过敏原免疫疗法 (AIT) 在管理LAR方面表现出有希望的结果.
- LAR显著影响患者的生活质量.
结论:
- 测量鼻腔sIgE可以提高LAR诊断.
- 对LAR来说,AIT是一种可行的,有前途的治疗选择.
- 需要进一步的研究来充分评估AIT的疗效和LAR的长期结果.
相关概念视频
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Asthma: Pathogenesis and Management
467
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
467
Drugs Used in Lower Respiratory Disorders: Overview
509
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
509
Allergic Reactions
27.9K
Overview
27.9K
Drugs Used in Upper Respiratory Disorders: Overview
300
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
300
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
361
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
361


